Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic polymorphisms in XPG could predict clinical outcome of platinum-based chemotherapy for advanced non-small cell lung cancer.

Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine - 1 Jun 2014

Hu Weicai, Pan Jinbing, Zhao Pu, Yang Guangyu, Yang Shujuan

Abstract excerpt

We conducted a prospective study to investigate the role of four single nucleotide polymorphisms (SNPs) of XPG on the clinical outcome of advanced non-small cell lung cancer (NSCLC) treated with platinum-based doublets chemotherapy. In total, 277 patients with histologically confirmed NSCLC were mainly from December 2007 and December 2008. The genotypes of rs2296147T>C, rs1047768C>T, rs873601G>A, and rs17655G>C...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Endonucleases

Share to Lung Neoplasms

Share to Nuclear Proteins

Share to Platinum

Share to Proportional Hazards Models

Share to Treatment Outcome

Source

Identifiers

PMID: 24615519
DOI: 10.1007/s13277-014-1732-4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic polymorphisms in XPG could predict clinical outcome of platinum-based chemotherapy for advanced non-small cell lung cancer.PMID 24615519Read ↗

XPG is predictive gene of clinical outcome in advanced non-small-cell lung cancer with platinum drug therapy.Semantic proximity Read ↗

XPG polymorphisms are associated with prognosis of advanced non-small cell lung cancer treated with platinum-based doublet chemotherapy.Semantic proximity Read ↗

Genetic Polymorphisms and Platinum-based Chemotherapy Treatment Outcomes in Patients with Non-Small Cell Lung Cancer: A Genetic Epidemiology Study Based Meta-analysis.Semantic proximity Read ↗

Effects of polymorphisms in the XRCC1, XRCC3, and XPG genes on clinical outcomes of platinum-based chemotherapy for treatment of non-small cell lung cancer.Semantic proximity Read ↗

Effect of GSTP1 and ABCC2 Polymorphisms on Treatment Response in Patients with Advanced Non-Small Cell Lung Cancer Undergoing Platinum-Based Chemotherapy: A Study in a Chinese Uygur Population.Semantic proximity Read ↗

Association of Base Excision Repair Gene Polymorphisms with the Response to Chemotherapy in Advanced Non-Small Cell Lung Cancer.Semantic proximity Read ↗

The association between the ERCC1/2 polymorphisms and the clinical outcomes of the platinum-based chemotherapy in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis.Semantic proximity Read ↗

Polymorphisms in the base excision repair pathway modulate prognosis of platinum-based chemotherapy in advanced non-small cell lung cancer.Semantic proximity Read ↗

Effect of polymorphisms in XPD on clinical outcomes of platinum-based chemotherapy for Chinese non-small cell lung cancer patients.Semantic proximity Read ↗

XRCC1 Arg399Gln and clinical outcome of platinum-based treatment for advanced non-small cell lung cancer: a meta-analysis in 17 studies.Semantic proximity Read ↗

Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients.Semantic proximity Read ↗

Role of ERCC1 variants in response to chemotherapy and clinical outcome of advanced non-small cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.